Wellgistics Health Begins Commercial Launch Of Diabetes Prescription Drug Brenzavvy To Wellgistics Pharmacy Network

Launch targets $16 billion SGLT-2 inhibitor market that serves 33 million type II diabetics in the US, many of whom are uninsured and underinsured and whose out-of-pocket costs exceed Brenzavvy's cash price

Proprietary EinsteinRx™ artificial intelligence pharmacy platform empowers the 6,500+ pharmacies in the Wellgistics Pharmacy Network to educate patients and providers on the advantages of Brenzavvy vs. Jardiance® and other SGLT-2 inhibitors

Reduced out-of-pocket costs for patients, paired with a patient-education revenue opportunity for pharmacists, are designed to support broader market access to Brenzavvy and enhance the overall care experience

Launch establishes a new model for next-generation reformulated drugs that offer patient-specific product advantages compared with entrenched market leaders

TAMPA, FL / ACCESS Newswire / December 8, 2025 / Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today announced that it has begun the commercial launch of diabetes prescription drug Brenzavvy® to its network of 6,500 independent pharmacies (the "Wellgistics Pharmacy Network") that primarily target patients in rural communities where there is often an increased incidence of diabetes. The launch is targeting the 33 million Americans who have been diagnosed with type II diabetes[1] and whose out-of-pocket costs for SGLT-2 drugs exceed the Brenzavvy cash price.

Jardiance® and other SGLT-2 inhibitor drugs reached sales of $16.8 billion in 2024, with projected growth projected to reach $28.9 billion by 2033. The United States represents 40.8% of that market according to Grandview Research[2]. A large scale analysis of data from 28 US health systems in 2022-2023 showed that guideline-recommended prescription of SGLT-2 inhibitors in diabetics with a class 1A recommendation is only 11.9%[3], leading to suboptimal care for the vast majority of such patients. As the Company's proprietary EinsteinRx artificial intelligence pharmacy platform is being rolled out into the Wellgistics Pharmacy Network's point-of-sales systems, Wellgistics will alert pharmacists to patients with a likely class 1A recommendation for a SGLT-2 inhibitor, as well as the likely patient benefit from dispensing Brenzavvy vs. other SGLT-2 inhibitors in the majority of cases where such a class 1A recommendation does not exist. Once alerted, pharmacists will be able to work to rapidly educate the provider on the benefits of Brenzavvy vs. other SGLT-2 inhibitors in patients without cardiovascular disease or chronic kidney disease (CKD). Brenzavvy's competitive price point when compared with the out-of-pocket costs of Jardiance & other SGLT-2 inhibitors, provides a compelling rationale for pharmacist-driven education of providers to help optimize prescribing decisions and help improve patient access.